» Articles » PMID: 21749900

Significance of Talin in Cancer Progression and Metastasis

Overview
Publisher Elsevier
Date 2011 Jul 14
PMID 21749900
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Upon detachment from the extracellular matrix, tumor epithelial cells and tumor-associated endothelial cells are capable of overcoming anoikis, gain survival benefits, and hence contribute to the process of metastasis. The focal-adhesion complex formation recruits the association of key adaptor proteins such as FAK (focal-adhesion kinase). Vimentin, paxillin, and talin are responsible for mediating the interaction between the actin cytoskeleton and integrins. Talin is an early-recruited focal-adhesion player that is of structural and functional significance in mediating interactions with integrin cytoplasmic tails leading to destabilization of the transmembrane complex and resulting in rearrangements in the extracellular integrin compartments that mediate integrin activation. Talin-mediated integrin activation plays a definitive role in integrin-mediated signaling and induction of downstream survival pathways leading to protection from anoikis and consequently resulting in cancer progression to metastasis. We recently reported that talin expression is significantly increased in prostate cancer compared with benign and normal prostate tissue and that this overexpression correlates with progression to metastatic disease implicating a prognostic value for talin during tumor progression. At the molecular level, talin is functionally associated with enhanced survival and proliferation pathways and confers anoikis resistance and metastatic spread of primary tumor cells via activation of the Akt survival pathway. In this review, we discuss the growing evidence surrounding the value of talin as a prognostic marker of cancer progression to metastasis and as therapeutic target in advanced prostate cancer, as well as the current understanding of mechanisms regulating its signaling activity in cancer.

Citing Articles

A Review of Talin- and Integrin-Dependent Molecular Mechanisms in Cancer Invasion and Metastasis.

Baster Z, Russell L, Rajfur Z Int J Mol Sci. 2025; 26(5).

PMID: 40076426 PMC: 11899650. DOI: 10.3390/ijms26051798.


High-resolution snapshots of the talin auto-inhibitory states suggest roles in cell adhesion and signaling.

Rangarajan E, Bois J, Hansen S, Izard T Nat Commun. 2024; 15(1):9270.

PMID: 39468080 PMC: 11519669. DOI: 10.1038/s41467-024-52581-2.


Physiological Responses to Acute Heat Stress in Rohu, Labeo rohita: Insights from Liver Proteomics.

Badhe M, Das P, Sahoo S, Paul A, Sahoo P, Reddy R Mar Biotechnol (NY). 2024; 26(6):1129-1142.

PMID: 39207653 DOI: 10.1007/s10126-024-10360-6.


Role of Kindlin 2 in prostate cancer.

Bialkowska K, El Khalki L, Rana P, Wang W, Lindner D, Parker Y Sci Rep. 2024; 14(1):19809.

PMID: 39191802 PMC: 11349918. DOI: 10.1038/s41598-024-70202-2.


Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing Cancer Metastasis.

Tsai H, Chen C, Chang T, Fu C, Chen W, Perez S Int J Mol Sci. 2024; 25(8).

PMID: 38673867 PMC: 11050067. DOI: 10.3390/ijms25084283.


References
1.
OToole T, Mandelman D, Forsyth J, Shattil S, Plow E, Ginsberg M . Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science. 1991; 254(5033):845-7. DOI: 10.1126/science.1948065. View

2.
Tantivejkul K, Kalikin L, Pienta K . Dynamic process of prostate cancer metastasis to bone. J Cell Biochem. 2004; 91(4):706-17. DOI: 10.1002/jcb.10664. View

3.
Schaller M, Hildebrand J, Shannon J, Fox J, Vines R, Parsons J . Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994; 14(3):1680-8. PMC: 358526. DOI: 10.1128/mcb.14.3.1680-1688.1994. View

4.
Graham T, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K, Tighiouart M . Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68(7):2479-88. DOI: 10.1158/0008-5472.CAN-07-2559. View

5.
Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View